1. Exploring the Molecular Players behind the Potentiation of Chemotherapy Effects by Durvalumab in Lung Adenocarcinoma Cell Lines
   Marika Saar et al, 2023, Pharmaceutics CrossRef
2. Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor in vivo acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncology
   Iméne Ben Toumia et al, 2024, Front. Pharmacol. CrossRef
3. Interaction between NSCLC Cells, CD8+ T-Cells and Immune Checkpoint Inhibitors Potentiates Coagulation and Promotes Metabolic Remodeling—New Cues on CAT-VTE
   Catarina Freitas-Dias et al, 2024, Cells CrossRef
4. Lung Cancer in Estonia
   Tanel Laisaar et al, 2024, Journal of Thoracic Oncology CrossRef
5. Editorial: Advances in novel pharmacotherapeutics and drug discovery: computational, experimental, translational, and clinical models
   Cristian Sandoval et al, 2024, Front. Pharmacol. CrossRef
6. The Role of m6A Methylation in Tumor Immunity and Immune-Associated Disorder
   Siyu Mu et al, 2024, Biomolecules CrossRef